✦ LIBER ✦

The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)

✍ Scribed by Skřičková, Jana; Bortlíček, Zdeněk; Hejduk, Karel; Pešek, Miloš; Zatloukal, Petr; Kolek, Vítězslav; Salajka, František; Koubková, Leona; Čoupková, Helena; Zemanová, Milada

Book ID: 119320891
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 46 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.075

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of pemetrexed as first line treatmen

Use of pemetrexed as first line treatment of advanced non-small cell lung cancer: The Czech Republic experience with the treatment of 237 patients (pts)

✍ Skřičková, Jana; Bortlíček, Zdeněk; Hejduk, Karel; Pešek, Miloš; Kolek, Vítězsla 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Erlotinib treatment results in patients

Erlotinib treatment results in patients with advanced non-small-cell lung cancer (NSCLC)—Influence of clinical predictors

✍ Salajka, F.; Pešek, M.; Skřičková, J.; Zatloukal, P.; Koubková, L.; Grygárková, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

19 Erlotinib in the treatment of non-sma

19 Erlotinib in the treatment of non-small-cell lung cancer

✍ Kyte, J.; Wilson, P.C.; Dangoor, A. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Gefitinib in the treatment of elderly pa

Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)

✍ Bearz, Alessandra; Fratino, Lucia; Spazzapan, Simon; Berretta, Massimiliano; Gia 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Use of erlotinib in patients selected us

Use of erlotinib in patients selected using clinical criteria in the 2nd and 3rd line treatment of non-small cell lung cancer (NSCLC)

✍ Stavridi, F.; Eestila, S.; Merchant, S.; Cane, P.; Spicer, J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Erlotinib as first-line treatment of Eur

Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)

✍ Petruzelka, Lubos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB